Biotec Pharmacon ASA reported earnings results for the third quarter nine months of 2013. For the quarter, the company reported sales revenues were NOK 6.3 million against NOK 4.0 million a year ago. LBITDA was NOK 4.4 million against NOK 6.4 million a year ago. Loss before tax was NOK 5.0 million against NOK 7.0 million a year ago. Cash flow used in operating activities was NOK 6.765 million against NOK 6.683 million a year ago.

For the nine months, the company reported sales revenues were NOK 16.8 million against NOK 15.4 million a year ago. LBITDA was NOK 15.2 million against NOK 16.2 million a year ago. Loss before tax was NOK 16.9 million against NOK 17.8 million a year ago. Cash flow used in operating activities was NOK 16.488 million against NOK 20.864 million a year ago. Cash flow used in operating activities was NOK 16.488 million against NOK 20.864 million a year ago.